Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (1056)	3/4/2000 7:55:00 PM
From: Zvi Steinberg	Respond to of 1386

Insha'Allah!!

To: David Israel-Rosen who wrote (1056)	3/4/2000 8:09:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 1386

Rat studies will not a Bgen market price bring, not even 25%, Pharmos has excellent animal models of trauma for several years now and the price did not respond to it. In any case Tamoxifen metabolites should be the ones to bring the price to $100 faster and easier cause there are the offspring of a proven product, since there is not doubt tamoxifen work. MS is a mid size market, much smaller than trauma or stroke, constant chronic use brings a long term flow of cash, but already with some good drugs in use, and long term use will bring a need to prove dexanabinol as good safety long term which is not the same as the actual proven short term safety. The $80 to $100 will also need of a constant biotech hype wave and this is not a certainty but the other way:deflation Current PARS valuation in percentage gain is in tamden with the rest of biotech, some 500% to 1000% in two months, I strongly doubt similar gains, maybe 50% to 100% at most, if at all. Most probably a dip is coming.